News

Compass Pathways’ psilocybin drug application heads to the FDA 

By Ella Ruder 1 min read

Biotechnology company Compass Pathways has completed its new drug application to the FDA for COMP360, an investigational synthetic psilocybin formulation for treatment-resistant depression, the company said Nov. 9. The application rests on two phase 3 trials and a phase 2b study. Each met its primary endpoint, and together they enrolled more than 1,000 patients with chronic treatment-resistant depression. Compass expects to launch COMP360 in the first half of 2027 if the FDA approves it. The FDA had already granted the drug rolling review and a Commissioner’s National Priority Voucher, which… Originally published in Becker’s Hospital Review. Read More

Share this post

Integrated Psychiatric Consultants

Office Hours:
Mon-Fri, 9 a.m. - 5 p.m. CT

Reach out today.

Integrated Psychiatric Consultants (IPC) is committed to protecting and respecting your privacy. Our team will use the information collected here solely to serve your needs and notify you about relevant services. To consent, please check the box above and submit this form.

Please note, this consent applies to all forms of communications, including SMS. If you have provided a mobile phone number above, you agree to receiving SMS messages from IPC. You may unsubscribe at any time. Message frequency varies. Messaging and data rates may apply. Reply STOP to cancel. For more information, please review our Privacy Policy.